On 26 & 27 April 2018, London will host the 16th Biosimilar Medicines conference. This year’s flagship event will gather top EU and global regulators, officials, healthcare actors as well as industry leaders, to foster open exchange and debate on the role of the biosimilar medicines sector in “Biosimilar Medicines: Unlocking the Full Potential of Biologics”. Over two days, participants will dive into a dynamic programme – a crossroads between technical, scientific, market discussions and the overarching healthcare policy agenda. With 15 years of experience-sharing on scientific assessment, regulatory approval and the introduction of biosimilar medicines in clinical practice, this conference will take us to new uncharted waters in preparing for this new era. Biosimilar medicines have been game changers in the therapeutic areas where they have been used (e.g. rheumatology, gastroenterology) with positive benefits on access to treatment, and therefore on patient outcomes. They are about to enter cancer patient pathways where the anticipated benefits will represent a unique opportunity for re-investment in needed healthcare products and services.
Free to join - no credit card required